What Is Entyvio Used For? Treating Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the lining of the colon and rectum, causing long-term inflammation and painful ulcers. People living with UC often experience abdominal pain, diarrhea, fatigue, and an unpredictable cycle of flare-ups and remissions. Managing this condition usually involves a mix of medication, dietary adjustments, and regular medical care to keep inflammation under control.

For those with moderate to severe ulcerative colitis who do not respond well to standard treatments like corticosteroids or immunosuppressants, biologic therapies offer a more targeted approach. One of the leading options is Entyvio (vedolizumab). It is a gut-selective biologic designed to calm inflammation by focusing directly on the digestive tract. Unlike some treatments that affect the entire immune system, Entyvio works locally, reducing inflammation where it starts while limiting effects elsewhere in the body.

This article explains what Entyvio is used for, how it helps treat ulcerative colitis, and what patients and clinicians can expect in terms of outcomes, safety, and long-term management.

Key Takeaways

• Entyvio (vedolizumab) has regulatory approval to treat moderately to severely active ulcerative colitis, Crohn’s disease, and chronic pouchitis in adults who failed or were intolerant to prior therapy.
• Its gut-selective mechanism reduces inflammation locally while preserving overall immune balance, improving both safety and long-term remission rates.
• A trained healthcare professional may administer Entyvio as IV infusions (for induction and maintenance) or subcutaneous injections (108 mg every 2 weeks) for maintenance therapy.
• Clinical trials like GEMINI 1 confirm strong results in symptom control, mucosal healing, and steroid-free remission.
• Supported by studies like VARSITY, experts use Entyvio after and before other biologics as a first-line therapy for bio-naïve patients.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to order Entyvio online for your practice, contact Doctor Medica today. 

Clinical Indications: Ulcerative Colitis and Crohn’s Use of Entyvio

When patients ask what Entyvio is used for, the answer extends beyond ulcerative colitis alone. Entyvio (vedolizumab) is approved for the treatment of moderately to severely active ulcerative colitis (UC), Crohn’s disease (CD), and chronic pouchitis in adults who have not responded adequately to other therapies. These chronic inflammatory bowel diseases damage the intestinal lining, leading to symptoms such as abdominal pain, diarrhea, rectal bleeding, and fatigue.

Approved Indications

• Ulcerative Colitis (UC): For adults with moderate to severe UC who have failed, lost response to, or were intolerant to conventional therapy (corticosteroids or immunomodulators) or a TNF antagonist.
  
• Crohn’s Disease (CD): For adults with moderate to severe disease requiring targeted inflammation control and fewer systemic side effects.
  
• Chronic Pouchitis: For adults with moderately to severely active chronic pouchitis who have failed antibiotic therapy after proctocolectomy with ileal pouch–anal anastomosis (IPAA).

Because Entyvio’s action is gut-selective, it works precisely where inflammation occurs while sparing other organs from unnecessary immune suppression. This targeted mechanism allows for long-term disease control with a lower likelihood of systemic complications.

Evidence Base in Ulcerative Colitis (Clinical Trials and Outcomes)

The clinical foundation supporting Entyvio’s use in ulcerative colitis is built on extensive research and large-scale studies. As a gut-selective biologic therapy, Entyvio has been tested across multiple phase III clinical trials, with the landmark GEMINI 1 study serving as pivotal evidence of its efficacy and safety.

Main Clinical Findings

• Induction Phase (6–10 weeks): Patients treated with Entyvio showed rapid improvement in hallmark UC symptoms, including reduced stool frequency, less rectal bleeding, and better overall well-being. These early responses often led to more durable control over time.
  
• Maintenance Phase (52 weeks): Continued treatment resulted in sustained remission, stable bowel habits, and less reliance on corticosteroids. Many patients achieved corticosteroid-free remission, a key goal in long-term UC care.
  
• Mucosal Healing: Beyond symptom relief, Entyvio promoted visible healing of intestinal tissue, an outcome strongly associated with fewer flare-ups, hospitalizations, and surgeries.

This strong evidence base confirms that Entyvio not only induces remission but also helps maintain long-term disease stability. Its gut-specific focus also supports a favorable safety profile compared with systemic biologics. For those interested in the underlying science, Entyvio’s mechanism of action explains how vedolizumab targets inflammation directly in the digestive tract while minimizing effects elsewhere in the body.

Role of Entyvio in Induction and Maintenance Therapy

Entyvio therapy is designed to manage every stage of the treatment journey—from rapid symptom relief to sustained remission. It is available in two formulations: intravenous (IV) infusion and subcutaneous (SC) injection.

Therapeutic Phases

• Induction Phase: Patients begin treatment with IV infusions at weeks 0, 2, and 6 to control inflammation and relieve symptoms.
  
• Maintenance Phase: After achieving remission, therapy continues with IV infusions every 8 weeks. For those who lose response, the dosing frequency may be increased to every 4 weeks.
  
• Subcutaneous Option: After at least two IV induction doses, patients may transition to a subcutaneous maintenance regimen of 108 mg every 2 weeks, offering convenience and continued disease control.
  
• Corticosteroid-Free Remission: Many patients can reduce or stop corticosteroid use, avoiding long-term side effects like bone loss or weight gain.

This flexible, phased approach provides both rapid symptom improvement and long-term inflammation control, making Entyvio a cornerstone therapy in chronic inflammatory bowel disease.

Practical Considerations and Patient Selection for Entyvio in UC

Choosing Entyvio involves a thorough evaluation of disease activity, treatment history, and individual therapeutic goals. Traditionally, a healthcare professional prescribes vedolizumab after failure of corticosteroids or TNF antagonists. However, current evidence from studies such as VARSITY supports its use as a first-line biologic in bio-naïve patients, especially those with ulcerative colitis, given its strong efficacy and safety outcomes.

Ideal Candidates

• Adults with moderate to severe ulcerative colitis unresponsive or intolerant to corticosteroids, immunomodulators, or TNF antagonists.
  
• Patients seeking corticosteroid-free remission and long-term mucosal healing.
  
• Individuals transitioning between biologics who require a safer, gut-targeted therapy.
  
• Those with chronic pouchitis not improving with antibiotic therapy.

Because Entyvio acts locally in the gastrointestinal tract, it minimizes systemic immune suppression while maintaining high therapeutic precision. Doctors may use it as a monotherapy or combine it with other UC treatments. With regular follow-up and monitoring, most individuals achieve better symptom control, fewer relapses, and an improved quality of life under this targeted biologic therapy.

Conclusion

Entyvio has become a cornerstone in modern ulcerative colitis and Crohn’s disease management. Its gut-selective mechanism, proven efficacy in both induction and maintenance, and expanding indications for pouchitis demonstrate its versatility and reliability.

As treatment strategies evolve, Entyvio increasingly serves as a frontline biologic option—bridging the gap between traditional therapies and precision medicine. Its ability to promote mucosal healing, support steroid-free remission, and maintain long-term safety reinforces its role as a trusted therapy for patients and clinicians alike.

FAQs

1. What does Entyvio do for ulcerative colitis?

Entyvio treats moderately to severely active ulcerative colitis in adults who have not responded to corticosteroids, immunomodulators, or TNF antagonists. It reduces inflammation, relieves symptoms, and helps maintain remission.

2. How is Entyvio administered?

Healthcare professionals administer it through IV infusion at weeks 0, 2, and 6 for induction, followed by every 8 weeks for maintenance. If response declines, they may give the infusions every 4 weeks. A subcutaneous maintenance injection (108 mg every 2 weeks) is also available after at least two IV doses.

3. Can Entyvio replace corticosteroids?

Yes. Entyvio can help achieve corticosteroid-free remission, allowing patients to taper or stop steroid therapy while maintaining disease control.

4. How does Entyvio compare to other biologics for UC?

Unlike systemic biologics that affect the entire immune system, Entyvio targets inflammation in the gut, providing effective disease control with fewer systemic side effects—an advantage for both patients and healthcare providers managing long-term IBD.

References

Centers for Disease Control and Prevention. IBD Facts and Stats. https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html

Clinical Advisor. Ulcerative Colitis Statistics. https://www.clinicaladvisor.com/features/ulcerative-colitis-statistics/

Clement B, De Felice K, Afzali A. Indications and safety of newer IBD treatments in the older patient. Current Gastroenterology Reports. 2023;25(7):160-168. doi:10.1007/s11894-023-00874-9